IP Library Granted Patent US 8,604,174
Granted Patent B2
US 8,604,174 · App. 11/911,940 · Granted Dec 10, 2013

High affinity fully human monoclonal antibodies to interleukin-8

Inventors: John Babcook (Vancouver, CA); Palaniswami Rathanaswami (Vancouver, CA); Orit Foord (Foster City, CA); Jaspal S. Kang (Surrey, CA)
Assignee: Amgen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,604,174
App. No.
11/911,940
Granted
Dec 10, 2013
Kind
B2
Abstract

The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided.

Claims (14)

1. An isolated monoclonal antibody, or antigen-binding portion thereof, that specifically binds to interleukin-8 (IL-8) comprising:

a heavy chain polypeptide comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NO: 23, and a light chain polypeptide comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NO: 21.

2. The monoclonal antibody or antigen-binding portion thereof of claim 1 ,

wherein the light chain CDR1 sequence is residues 24-34 of SEQ ID NO: 21,

wherein the light chain CDR2 sequence is residues 50-56 of SEQ ID NO): 21; and

wherein the light chain CDR3 sequence is residues 89-96 of SEQ ID NO: 21.

3. The monoclonal antibody or antigen-binding portion thereof of claim 2 , wherein the heavy chain variable region comprises a heavy chain CDR1 sequence, a heavy chain CDR2 sequence, and a heavy chain CDR3 sequence,

wherein the heavy chain CDR1 sequence is residues 26-35 of SEQ ID NO: 23;

wherein the heavy chain CDR2 sequence is residues 50-66 of SEQ ID NO: 23; and

wherein the heavy chain CDR3 sequence is residues 99-106 of SEQ ID NO: 23.

4. The monoclonal antibody of claim 1 , wherein the light chain comprises SEQ ID NO:21.

5. The monoclonal antibody claim 1 , wherein the heavy chain comprises SEQ ID NO:23.

6. The monoclonal antibody of claim 5 , wherein the light chain comprises SEQ ID NO:21.

7. The antibody of claim 1 , wherein the antibody reduces chemotaxis of neutrophils.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2008
From: BABCOOK, JOHN; RATHANASWAMI, PALANISWAMI; KANG, JASPAL S.; FOORD, ORIT
To: AMGEN FREMONT, INC.
Reel/Frame 020826/0901 →
Continuity (2)
Provisional Application 60473452 · Apr 20, 2005
Related Publication 20090130110A1 · May 21, 2009